Showing 4841-4850 of 5696 results for "".
- TearClear Raises $22M in Series B Fundinghttps://modernod.com/news/tearclear-raises-22m-in-series-b-funding/2478158/TearClear announced it has raised $22 million in a Series B funding round. The company intends to use the funds to advance multiple clinical programs in development, with two lead candidates in glaucoma paving the way for future indications. Led by Chief Executive Officer Robert Dempsey, T
- US Secures At Least 100 Million Doses of Moderna’s COVID-19 Vaccine for $1.5 Billionhttps://modernod.com/news/us-secures-at-least-100-million-doses-of-modernas-covid-19-vaccine-for-1-5-billion/2478151/Moderna on Tuesday said it reached an agreement with the US government to supply millions of doses of its coronavirus vaccine candidate mRNA-1273. The award of up to $1.525 billion is for the manufacturing and delivery of 100 million doses of the vaccine, including incentive payments for timely d
- Russia’s Approval of Virus Vaccine Greeted With Some Alarmhttps://modernod.com/news/russias-approval-of-virus-vaccine-greeted-with-some-alarm/2478146/Russia on Tuesday became the first country to approve a coronavirus vaccine for use in tens of thousands of its citizens despite international skepticism about injections that have not completed clinical trials and were studied in only dozens of pe
- Alcon Canada introduces PRECISION1 Contact Lenseshttps://modernod.com/news/alcon-canada-introduces-precision1-contact-lenses/2478144/Alcon has launched the PRECISION1 daily disposable, silicone hydrogel (SiHy) contact lenses in Canada. Designed to address the common issues that cause 1-in-5 new wearers to discontinue contact lens within the first year (poor vision, comfort and handling issues1), Precision1 he
- Clearside Biomedical Announces FDA Acceptance of Investigational NDA for CLS-AX Administered in Suprachoroidal Spacehttps://modernod.com/news/clearside-biomedical-announces-fda-acceptance-of-investigational-nda-for-cls-ax-administered-in-suprachoroidal-space/2478140/Clearside Biomedical announced that the FDA has accepted its investigational new drug (IND) application for CLS-AX (axitinib injectable suspension), enabling initiation of a phase 1/2a clinical trial of CLS-AX in wet age-related macular degeneration (AMD) patients by the end of 20
- CooperVision Acquires GP Specialists, Expanding Specialty EyeCare Business and Ortho-K Optionshttps://modernod.com/news/coopervision-acquires-gp-specialists-expanding-specialty-eyecare-business-and-ortho-k-options/2478137/CooperVision has acquired C&E GP Specialists, a customized orthokeratology contact lens manufacturer and distributor. The move expands CooperVision’s Specialty eye care business. Terms of the deal were not disclosed. “CooperVision is committed to providing eye care professionals
- Johnson & Johnson Forges $1-Billion Pact to Supply US with COVID-19 Vaccinehttps://modernod.com/news/johnson-johnson-forges-1-billion-pact-to-supply-us-with-covid-19-vaccine/2478133/Johnson & Johnson said it entered into an agreement with the US government for the large-scale domestic manufacturing and delivery of 100 million doses of its investigational SARS-CoV-2 vaccine Ad26.COV2.S for use in the country. Specifically, the US Biomedical Advanced Research and Developme
- Gyroscope Announces Appointment of Leaders in Retinal Disease, Gene Therapy and the Complement System to Advisory Boardshttps://modernod.com/news/gyroscope-announces-appointment-of-leaders-in-retinal-disease-gene-therapy-and-the-complement-system-to-advisory-boards/2478130/Gyroscope Therapeutics announced the appointment of leading experts in retinal disease, gene therapy, and the complement system to its Clinical and Scientific advisory boards. The newly appointed boards will help guide the development of the company’s lead investigational gene therapy, GT00
- Palatin Technologies Completes Enrollment of Phase 2 Study for Dry Eye Disease Treatment Candidatehttps://modernod.com/news/palatin-technologies-announces-completion-of-enrollment-of-phase-2-study-with-pl9643-for-the-treatment-of-dry-eye-disease/2478124/Palatin Technologies announced completion of enrollment of its phase 2 study with PL9643 for the treatment of dry eye disease (DED). After delaying enrollment of new patient groups due to the COVID-19 pandemic, Palatin reinitiated enrollment in its PL9643 phase 2 clinical study in subjects
- Eyenuk Announces FDA Clearance for EyeArt Autonomous AI System for Diabetic Retinopathy Screeninghttps://modernod.com/news/eyenuk-announces-fda-clearance-for-eyeart-autonomous-ai-system-for-diabetic-retinopathy-screening/2478123/Eyenuk announced it has received 510(k) clearance by the FDA to market its EyeArt autonomous AI System for diabetic retinopathy. EyeArt is indicated for use by health care providers to automatically detect more than mild diabetic retinopathy (mtmDR) and vision-threatening diabetic retinopa